Trius Therapeutics Presents Clinical Data on Experimental Antibiotic Tedizolid at ECCMID Meeting

Trius Therapeutics Presents Clinical Data on Experimental Antibiotic Tedizolid
at ECCMID Meeting

First Scientific Conference Presentations on Results of Multiple Clinical
Studies of Tedizolid Phosphate Including the ESTABLISH-2 Phase 3 Trial

SAN DIEGO and BERLIN, April 29, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics,
Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and
development of antibiotics for serious infections, announced a range of
clinical data for the experimental antibiotic tedizolid phosphate (TR-701) and
a presentation on linezolid (Zyvox®)-resistant strain of bacteria. This took
place at the European Congress of Clinical Microbiology and Infectious
Diseases (ECCMID) meeting in Berlin.

In addition to the detailed efficacy and safety results of the ESTABLISH-2
study, which build upon the top-line results previously announced, Trius
presented the results of a drug interaction clinical study demonstrating that
tedizolid phosphate does not increase blood pressure when used in conjunction
with vasoconstrictor drugs such as decongestants. In addition, the results of
a separate clinical cardiovascular safety study showed that tedizolid is not
associated with heart beat abnormalities at up to six times its effective
dose, the maximum dose examined in the study. The results of both studies
further support the safety profile for tedizolid. In addition, in an oral
presentation, Trius provided an overview of data on an emerging class of
bacterial pathogens that is resistant to linezolid (Zyvox), the only marketed
drug of the same class as tedizolid. To date, these strains have proven
susceptible to tedizolid.

"There has been a significant need for new antibiotic therapies targeting
resistant bacterial infections, such as MRSA," said Jeffrey Stein, Ph.D., CEO
and President of Trius Therapeutics."We are very excited to share these
results, which build upon and are consistent with those from our first Phase 3
study. These combined results show that tedizolid phosphate represents a
potential new therapy to treat severe skin infections with a once daily
intravenous infusion or pill in fewer days than existing antibiotic
medications. Combined with the results of our multiple other clinical and
nonclinical studies, we believe that tedizolid may offer substantial benefits
to patients and, potentially, payers and the healthcare system."

"The data demonstrate that in this trial tedizolid was safe and effective and
allowed patients to rapidly transition from an intravenous to pill therapy,"
said Philippe Prokocimer, M.D., Chief Medical Officer at Trius. "The combined
results of all of our clinical studies are remarkably consistent, and support
tedizolid as a well-tolerated, short-course therapy for acute bacterial skin

Copies of the posters are available on the Trius website:

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of innovative antibiotics for
serious infections. The Company's lead investigational drug, tedizolid
phosphate, is a novel antibiotic in Phase 3 clinical development for the
treatment of serious gram-positive infections, including those caused by
methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with
Bayer HealthCare for the development and commercialization of tedizolid
phosphate outside of the U.S., Canada and the European Union. In addition to
the Company's tedizolid phosphate clinical program, Trius has initiated
Investigational New Drug (IND) enabling studies for its Gyrase-B development
candidate with potent activity against Gram-negative bacterial pathogens
including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter
and Pseudomonas.For more information, visit

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, statements regarding the anticipated effects
of the addition of Mr. Fischer to the Company's Board of Directors and the
Company's commercialization efforts. Risks that contribute to the uncertain
nature of the forward-looking statements include: the accuracy of Trius'
estimates regarding expenses, future revenues and capital requirements; the
success and timing of Trius' preclinical studies and clinical trials;
regulatory developments in the United States and foreign countries; changes in
Trius' plans to develop and commercialize its product candidates; additional
ongoing or planned clinical trials of tedizolid phosphate may produce negative
or inconclusive results; Trius may decide, or the FDA may require Trius, to
conduct additional clinical trials or to modify Trius' ongoing clinical
trials; Trius may experience delays in the commencement, enrollment,
completion or analysis of clinical testing for its product candidates, or
significant issues regarding the adequacy of its clinical trial designs or the
execution of its clinical trials, which could result in increased costs and
delays, or limit Trius' ability to obtain regulatory approval; the third
parties with whom Trius has partnered with for the development of tedizolid
phosphate and upon whom Trius relies to conduct its clinical trials and
manufacture its product candidates may not perform as expected; tedizolid
phosphate may not receive regulatory approval or be successfully
commercialized; unexpected adverse side effects or inadequate therapeutic
efficacy of tedizolid phosphate could delay or prevent regulatory approval or
commercialization; Trius' ability to obtain and maintain intellectual property
protection for its product candidates; and the loss of key scientific or
management personnel. These and other risks and uncertainties are described
more fully in Trius' most recent Form 10-K, Forms 10-Q and other documents
filed with the United States Securities and Exchange Commission, including
those factors discussed under the caption "Risk Factors" in such filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Trius undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

CONTACT: Public Relations Contact:
         Laura Kempke/Andrew Law at MSLGROUP
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
Press spacebar to pause and continue. Press esc to stop.